BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1152 related articles for article (PubMed ID: 27621210)

  • 1. Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints.
    Chen YC; Kuo SF; Chen FJ; Lee CH
    Mycoses; 2017 Feb; 60(2):89-95. PubMed ID: 27621210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
    Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
    Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
    Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
    J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifungal susceptibility of Candida isolates at one institution.
    Katsuragi S; Sata M; Kobayashi Y; Miyoshi T; Yamashita Y; Neki R; Horiuchi C; Yamanaka K; Kamiya C; Iwanaga N; Tanaka H; Ikeda T; Yoshimatsu J
    Med Mycol J; 2014; 55(1):E1-7. PubMed ID: 24682093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical manifestations of candidemia caused by uncommon Candida species and antifungal susceptibility of the isolates in a regional hospital in Taiwan, 2007-2014.
    Liu WL; Lai CC; Li MC; Wu CJ; Ko WC; Hung YL; Tang HJ; Hsueh PR
    J Microbiol Immunol Infect; 2019 Aug; 52(4):612-619. PubMed ID: 28886952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing epidemiology of candidaemia in Australia.
    Chapman B; Slavin M; Marriott D; Halliday C; Kidd S; Arthur I; Bak N; Heath CH; Kennedy K; Morrissey CO; Sorrell TC; van Hal S; Keighley C; Goeman E; Underwood N; Hajkowicz K; Hofmeyr A; Leung M; Macesic N; Botes J; Blyth C; Cooley L; George CR; Kalukottege P; Kesson A; McMullan B; Baird R; Robson J; Korman TM; Pendle S; Weeks K; Liu E; Cheong E; Chen S;
    J Antimicrob Chemother; 2017 Apr; 72(4):1103-1108. PubMed ID: 28364558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
    Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
    Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.
    Wang H; Xu YC; Hsueh PR
    Future Microbiol; 2016 Oct; 11():1461-1477. PubMed ID: 27750452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region.
    Tan TY; Hsu LY; Alejandria MM; Chaiwarith R; Chinniah T; Chayakulkeeree M; Choudhury S; Chen YH; Shin JH; Kiratisin P; Mendoza M; Prabhu K; Supparatpinyo K; Tan AL; Phan XT; Tran TT; Nguyen GB; Doan MP; Huynh VA; Nguyen SM; Tran TB; Van Pham H
    Med Mycol; 2016 Jul; 54(5):471-7. PubMed ID: 26868904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.
    Posteraro B; Spanu T; Fiori B; De Maio F; De Carolis E; Giaquinto A; Prete V; De Angelis G; Torelli R; D'Inzeo T; Vella A; De Luca A; Tumbarello M; Ricciardi W; Sanguinetti M
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3944-55. PubMed ID: 25896705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal susceptibilities of Candida isolates causing bloodstream infections at a medical center in Taiwan, 2009-2010.
    Huang YT; Liu CY; Liao CH; Chung KP; Sheng WH; Hsueh PR
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3814-9. PubMed ID: 24752274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskou A; Ramani R
    Diagn Microbiol Infect Dis; 2012 Aug; 73(4):365-8. PubMed ID: 22726528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.
    Schmalreck AF; Willinger B; Haase G; Blum G; Lass-Flörl C; Fegeler W; Becker K;
    Mycoses; 2012 May; 55(3):e124-37. PubMed ID: 22233267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APX001A
    Arendrup MC; Chowdhary A; Astvad KMT; Jørgensen KM
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016-2018).
    Arastehfar A; Yazdanpanah S; Bakhtiari M; Fang W; Pan W; Mahmoudi S; Pakshir K; Daneshnia F; Boekhout T; Ilkit M; Perlin DS; Zomorodian K; Zand F
    Med Mycol; 2021 May; 59(5):422-430. PubMed ID: 32692816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal susceptibility of bloodstream Candida isolates in Sfax hospital: Tunisia.
    Sellami A; Sellami H; Néji S; Makni F; Abbes S; Cheikhrouhou F; Chelly H; Bouaziz M; Hammami B; Ben Jemaa M; Khaled S; Ayadi A
    Mycopathologia; 2011 Jun; 171(6):417-22. PubMed ID: 21170738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
    Pfaller MA; Castanheira M; Messer SA; Jones RN
    Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia.
    Lindberg E; Hammarström H; Ataollahy N; Kondori N
    Sci Rep; 2019 Mar; 9(1):3838. PubMed ID: 30846717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.